➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Johnson and Johnson
AstraZeneca
Dow

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for ASP2215

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for ASP2215?

ASP2215 is an investigational drug.

There have been 19 clinical trials for ASP2215. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Astellas Pharma Global Development, Inc., Astellas Pharma Inc, and National Cancer Institute (NCI).

There are two US patents protecting this investigational drug and forty-one international patents.

Recent Clinical Trials for ASP2215
TitleSponsorPhase
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsNational Cancer Institute (NCI)Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsChildren's Oncology GroupPhase 3
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Astellas Pharma Global Development, Inc.Phase 1/Phase 2

See all ASP2215 clinical trials

Clinical Trial Summary for ASP2215

Top disease conditions for ASP2215
Top clinical trial sponsors for ASP2215

See all ASP2215 clinical trials

US Patents for ASP2215

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASP2215   Start Trial Diamino heterocyclic carboxamide compound Astellas Pharma Inc. (Tokyo, JP) Kotobuki Pharmaceutical Co., Ltd. (Hanishina-gun, JP)   Start Trial
ASP2215   Start Trial Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (Tokyo, JP) KOTOBUKI PHARMACEUTICAL CO., LTD. (Nagano, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASP2215

Drugname Country Document Number Estimated Expiration Related US Patent
ASP2215 Australia 2010245545 2029-05-08   Start Trial
ASP2215 Brazil PI1011838 2029-05-08   Start Trial
ASP2215 Canada 2760061 2029-05-08   Start Trial
ASP2215 China 102421761 2029-05-08   Start Trial
ASP2215 Cyprus 1117546 2029-05-08   Start Trial
ASP2215 Cyprus 1120367 2029-05-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Johnson and Johnson
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.